Evoke Pharma Inc
NASDAQ:EVOK
Evoke Pharma Inc
NASDAQ:EVOK
Price:
29.9
USD
2.93%
Market Cap:
$25.5m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Evoke Pharma Inc
NASDAQ:EVOK
|
US |
|
Altius Renewable Royalties Corp
TSX:ARR
|
CA |
|
Miquel y Costas & Miquel SA
MAD:MCM
|
ES |
|
Daily Journal Corp
NASDAQ:DJCO
|
US |
|
A
|
AKITA Drilling Ltd
TSX:AKT.B
|
CA |
|
PJT Partners Inc
NYSE:PJT
|
US |
|
M
|
Mobimo Holding AG
XMUN:M1H
|
CH |
|
H
|
Honeywell Automation India Ltd
BSE:517174
|
IN |
|
GI Technologies Group Co Ltd
SZSE:300309
|
CN |
|
S
|
Substrate Artificial Inteligence SA
MAD:SAI
|
ES |
|
U
|
United Homes Group Inc
NASDAQ:UHG
|
US |
|
Ether Capital Corp
OTC:DTSRF
|
CA |
|
I
|
IBI Investment House Ltd
TASE:IBI
|
IL |
|
N
|
New Nordic Healthbrands AB
STO:NNH
|
SE |
|
S
|
Shandong Weigao Blood Purification Products Co Ltd
SSE:603014
|
CN |
Multiples-Based Value
The
Multiples-Based Value for
Evoke Pharma Inc (EVOK)
under the Base Case is
hidden
USD.
Compared with the current market price of 29.9 USD, the stock appears
hidden
.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
EVOK Multiples-Based Value
LOCKED
Multiples Across Competitors
EVOK Competitors Multiples
Evoke Pharma Inc Competitors
Evoke Pharma Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Evoke Pharma Inc
NASDAQ:EVOK
|
25.5m USD | 1.8 | -4.9 | -3.6 | -3.6 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
869B USD | 13.8 | 43.7 | 29.5 | 31.5 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
588.6B USD | 6.2 | 21.9 | 15.2 | 18.7 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4.1 | 19.4 | 11.5 | 13 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
233B GBP | 5.3 | 30.6 | 16.9 | 23.8 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
297.7B USD | 4.6 | 16.4 | 10.1 | 12.4 | |
| CH |
|
Novartis AG
SIX:NOVN
|
231.9B CHF | 5.4 | 21.7 | 13.4 | 17.3 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
237.1B USD | 102.3 | -81.1 | 375.3 | 941.3 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
159.7B USD | 2.6 | 20.9 | 7.9 | 10.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1T DKK | 3.4 | 10.3 | 7.6 | 8.9 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
122.1B USD | 2.6 | 17.6 | 7.4 | 9.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
